Chronological Timeline
|
| . 1462 The Hirsch pharmacy is opened in Frankfurt am Main. The Fresenius family assumes ownership in the 18th century. 1912 The pharmacist and proprietor of the Hirsch Pharmacy, Dr. Eduard Fresenius, founds the pharmaceutical company Dr. E. Fresenius. Its main products are pharmaceutical specialities such as injection solutions, serologic reagents and Bormelin nasal ointment. 1933/34 The manufacturing company is separated from the Hirsch Pharmacy and moves to Bad Homburg. Dr. Fresenius devotes more and more time to the company, which grows to around 400 employees. 1966 Fresenius starts to sell dialysis machines and dialyser manufactured various foreign companies and gains substantial market shares. 1971/74 Introduction of a novel amino acid solution achieving a decisive breakthrough in parenteral nutrition therapy. Development of an innovative volume replacement solution (hydroxyethyl starch solution - HES) in the field of fluid therapy/blood substitution. 1974 Fresenius starts to manufacture infusion solutions and medical disposables in St. Wendel, Saarland. 1979 The first ready-to use tube feed Fresubin® was introduced. 1980 Introduction of HAES-steril®, a further development of the hydroxyethyl starch solution with which Fresenius sets worldwide standards in volume therapy. 1984 Establishment of the home care concept by which patients who have to be fed enterally (intake of nutrients involving the gastro-intestinal tract) can be cared for at home. At the same time expansion of the enteral nutrition range. 1988 The within Fresenius developed Aminomix® Two-Chamber-Bag for parenteral nutrition launched. 1993 Launch of Supportan®, a tube feed for enteral nutrition in oncology. 1995 Laying of the cornerstone of the innovative infusion solution plant in Friedberg (Hesse). 1997 Introduction of the world’s first dipeptide solution for parenteral nutrition. Inauguration of the state-of-the-art infusions solutions plant (Friedberg, Hesse), the most modern one in Europe. 1999 Fresenius Kabi is formed by combining Fresenius Group's Pharma division with the infusion solution business acquired from Pharmacia & Upjohn (Kabi). The new company is Europe's leader in the field of nutrition and infusion therapy, offering a comprehensive product and service portfolio worldwide for hospitals and patients at home. Launch of a new generation of hydroxyethyl starch for volume therapy. 2000 Fresenius Kabi accelerated its worldwide business expansion by opening up new growth markets in Asia, Africa and Latin America. 2003 The business segment Fresenius HemoCare was reallocated within the Fresenius Group. Due to their similar technology platform, the Infusion Technology and Transfusion Technology Divisions were combined under one management and assigned to Fresenius Kabi. 2004 Fresenius Kabi strengthens its market positions with acquisitions in South Africa and Czech Republic as well as with a joint venture in Australia. 2005 Expansion of I.V. drug portfolio via acquisition of the Portugese pharmaceutical company Labesfal. Fresenius Kabi strengthens product portfolio and production network of medical devices through the acquisition of the business of Clinico. 2006 Fresenius Kabi and Sandoz to cooperate in the development of an HESylated biopharmaceutical drug. Acquisition of Argentinean pharmceutical company Filaxis: Expansion of I.V. drug portfolio. 2007 Fresenius Kabi strengthens business activities through acquisitions Blood volume replacement: Acquisition of blood volume replacement business of Japanese pharmaceutical company Kyorin I.V. Drugs: Acquisition of the Chilean company Laboratorio Sanderson and the Italian company Ribbon Clinical Nutrition: Acquisition of the enteral nutrition businesses from Nestlé in France and Spain. 2008 Fresenius Kabi grows its I.V. generics business and expands into oncology drugs with the Dabur Pharma acquisition. Fresenius Kabi enters into the North American pharmaceuticals market and becomes a globally leading company in the field of I.V. generics via the acquisition of the U.S. based APP Pharmaceuticals. |